


## AMENDMENTS TO THE CLAIMS

1. (Original) A compound of general formula (I)



I

wherein

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are independently hydrogen, halo, C<sub>1</sub>-C<sub>6</sub> alkyl, -O(C<sub>1</sub>-C<sub>6</sub> alkyl), -CON(R<sup>9</sup>)<sub>2</sub>, -SOR<sup>9</sup>, -SO<sub>2</sub>R<sup>9</sup>, -SO<sub>2</sub>N(R<sup>9</sup>)<sub>2</sub>, -N(R<sup>9</sup>)<sub>2</sub>, -NR<sup>9</sup>COR<sup>9</sup>, -CO<sub>2</sub>R<sup>9</sup>, -COR<sup>9</sup>, -SR<sup>9</sup>, -OH, -NO<sub>2</sub> or -CN;

each R<sup>9</sup> is independently hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl;

R<sup>5</sup> and R<sup>6</sup> are each independently hydrogen, or C<sub>1</sub>-C<sub>6</sub> alkyl or together with the carbon atom to which they are attached form a C<sub>3</sub>-C<sub>7</sub> cycloalkyl group;

R<sup>7</sup> is hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl

n is 1 or 2;

X is a bond or, when n is 2, X may also be a NR<sup>9</sup> group;

wherein R<sup>9</sup> is as defined above;

when X is a bond R<sup>8</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, biphenyl or a 9-14 membered bicyclic or tricyclic heteroaryl group;

when X is a  $\text{NR}^9$  group  $\text{R}^8$  may additionally be phenyl, naphthyl or a 5-7 membered heteroaromatic ring; and

the  $\text{R}^8$  group is optionally substituted with one or more substituents selected from halo,  $\text{C}_1\text{-C}_6$  alkyl,  $-\text{O}(\text{C}_1\text{-C}_6)\text{alkyl}$ , aryl,  $-\text{O-aryl}$ , heteroaryl,  $-\text{O-heteroaryl}$ ,  $-\text{CON}(\text{R}^9)_2$ ,  $-\text{SOR}^9$ ,  $-\text{SO}_2\text{R}^9$ ,  $\text{SO}_2\text{N}(\text{R}^9)_2$ ,  $-\text{N}(\text{R}^9)_2$ ,  $-\text{NR}^9\text{COR}^9$ ,  $-\text{CO}_2\text{R}^9$ ,  $-\text{COR}^9$ ,  $-\text{SR}^9$ ,  $-\text{OH}$ ,  $-\text{NO}_2$  or  $-\text{CN}$ ;

wherein  $\text{R}^9$  is as defined above;

or a pharmaceutically acceptable salt, hydrate, solvate, complex or prodrug thereof.

2-30. (Canceled)

31. (New) A compound as claimed in claim 1 wherein, independently or in any combination:

$\text{R}^1$  is halo or hydrogen;

$\text{R}^2$  is halo or hydrogen;

$\text{R}^3$  is halo or hydrogen;

$\text{R}^4$  is halo or hydrogen.

32. (New) A compound as claimed in claim 1 wherein  $\text{R}^1$ ,  $\text{R}^3$  and  $\text{R}^4$  are hydrogen and  $\text{R}^2$  is halo.

33. (New) A compound as claimed in claim 32 wherein  $\text{R}^2$  is fluoro.

34. (New) A compound as claimed in claim 1 wherein  $\text{R}^5$  and  $\text{R}^6$  are each independently hydrogen or  $\text{C}_1\text{-C}_4$  alkyl.

35. (New) A compound as claimed in claim 34 wherein at least one of  $R^5$  and  $R^6$  are hydrogen.

36. (New) A compound as claimed in claim 35 wherein both  $R^5$  and  $R^6$  are hydrogen.

37. (New) A compound as claimed in claim 1 wherein  $R^7$  is H or  $C_1-C_6$  alkyl.

38. (New) A compound as claimed in claim 37 wherein  $R^7$  is methyl.

39. (New) A compound as claimed in claim 1 wherein n is 2.

40. (New) A compound as claimed in claim 1 wherein X is a bond and  $R^8$  is  $C_1-C_6$  alkyl, biphenyl or a bicyclic heteroaryl group, any of which may be substituted with halogen, phenyl,  $-CO_2R^9$   $CON(R^9)_2$  or  $-SO_2R^9$ , where  $R^9$  is as defined in claim 1.

41. (New) A compound as claimed in claim 41 wherein  $R^8$  is selected from the group consisting of a  $C_1-C_4$  alkyl, biphenyl, and a bicyclic heteroaryl group, any of which may be substituted with phenyl,  $-CO_2R^9$   $CON(R^9)_2$  or  $-SO_2R^9$ , where  $R^9$  is H or  $C_1-C_4$  alkyl.


42. (New) A compound as claimed in claim 1 wherein X is  $NR^9$ ,  $R^9$  is H or methyl and  $R^8$  is selected from the group consisting of:

phenyl optionally substituted with one or more halo,  $C_1-C_6$  alkyl or  $-O(C_1-C_6$  alkyl) groups;

$C_1-C_6$  alkyl, optionally substituted with aryl; and  
heteroaryl.

43. (New) A compound as claimed in claim 42, wherein  $R^8$  is selected from the group consisting of phenyl, benzyl or pyridyl, any of which may optionally be substituted with one or more halo, methyl or methoxy groups.

44. (New) A compound of general formula (II):



II

wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $n$ ,  $X$ ,  $R^7$  and  $R^8$  are as defined for general formula (I);  $R^{10}$  is  $C_1$ - $C_6$  alkyl, aryl,  $(CH_2)_mOC(=O)C_1$ - $C_6$ alkyl,  $(CH_2)_mN(R^{11})_2$ ,  $CH((CH_2)_mO(C=O)R^{12})_2$ ;

$m$  is 1 or 2;

$R^{11}$  is hydrogen or methyl;

$R^{12}$  is  $C_1$ - $C_{18}$  alkyl.

45. (New) A compound as claimed in claim 15 wherein, independently or in any combination:

$R^1$  is halo or hydrogen;

$R^2$  is halo or hydrogen;

$R^3$  is halo or hydrogen;

$R^4$  is halo or hydrogen.

46. (New) A compound as claimed in claim 44 wherein  $R^1$ ,  $R^3$  and  $R^4$  are hydrogen and  $R^2$  is halo.

47. (New) A compound as claimed in claim 46 wherein  $R^2$  is fluoro.

48. (New) A compound as claimed in claim 44 wherein  $R^5$  and  $R^6$  are each independently hydrogen or  $C_1$ - $C_4$  alkyl.

49. (New) A compound as claimed in claim 48 wherein at least one of  $R^5$  and  $R^6$  are hydrogen.

50. (New) A compound as claimed in claim 38 wherein both  $R^5$  and  $R^6$  are hydrogen.

51. (New) A compound as claimed in claim 44 wherein  $R^7$  is H or  $C_1$ - $C_6$  alkyl.

52. (New) A compound as claimed in claim 51 wherein  $R^7$  is methyl.

53. (New) A compound as claimed in claim 44 wherein n is 2.

54. (New) A compound as claimed in claim 44 wherein X is a bond and  $R^8$  is  $C_1$ - $C_6$  alkyl, biphenyl or a bicyclic heteroaryl group, any of which may be substituted with halogen, phenyl,  $-CO_2R^9$   $CON(R^9)_2$  or  $-SO_2R^9$ , where  $R^9$  is as defined in claim 1.

55. (New) A compound as claimed in claim 54 wherein  $R^8$  is selected from the group consisting of a  $C_1$ - $C_4$  alkyl, biphenyl, a bicyclic heteroaryl group and a 5-7 membered heterocyclic ring, any of which may be substituted with phenyl,  $-CO_2R^9$   $CON(R^9)_2$  or  $-SO_2R^9$ , where  $R^9$  is H or  $C_1$ - $C_4$  alkyl.

56. (New) A compound as claimed in claim 44 wherein X is NR<sup>9</sup>, R<sup>9</sup> is H or methyl and R<sup>8</sup> is selected from the group consisting of:

phenyl optionally substituted with one or more halo, C<sub>1</sub>-C<sub>6</sub> alkyl or -O(C<sub>1</sub>-C<sub>6</sub> alkyl) groups;

C<sub>1</sub>-C<sub>6</sub> alkyl, optionally substituted with aryl; and  
heteroaryl.

57. (New) A compound as claimed in claim 56, wherein R<sup>8</sup> is selected from the group consisting of phenyl, benzyl or pyridyl, any of which may optionally be substituted with one or more halo, methyl or methoxy groups.

58. (New) A compound selected from the group consisting of:

[3-(Butane-1-sulfonyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid  
3-(Biphenyl-4-sulfonyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid  
(3-Carboxymethanesulfonyl-5-fluoro-2-methyl-indol-1-yl)-acetic acid  
(3-Carbamoylmethanesulfonyl-5-fluoro-2-methyl-indol-1-yl)-acetic acid  
[5-Fluoro-3-(2-methanesulfonyl-ethanesulfonyl)-2-methyl-indol-1-yl]-acetic acid  
[3-(Benzothiazole-2-sulfonyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid  
[3-(Benzothiazole-2-sulfinyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid  
[5-Fluoro-2-methyl-3-(quinoline-2-sulfonyl)-indol-1-yl]-acetic acid  
[5-Fluoro-2-methyl-3-(quinolin-8-ylsulfonyl)-indol-1-yl]-acetic acid  
(5-Fluoro-2-methyl-3-phenylmethanesulfonyl-1H-indol-1-yl)-acetic acid  
[3-(4-Chloro-phenylsulfamoyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid  
[3-(3-Chloro-phenylsulfamoyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid  
[3-(4-Fluoro-phenylsulfamoyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid

LAW OFFICES OF  
CHRISTENSEN O'CONNOR JOHNSON KINDNESS<sup>LLC</sup>  
1420 Fifth Avenue  
Suite 2800  
Seattle, Washington 98101  
206.682.8100

[3-(2-Chloro-phenylsulfamoyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid

(3-Benzylsulfamoyl-5-fluoro-2-methyl-indol-1-yl)-acetic acid

[5-Fluoro-3-(2-methoxy-phenylsulfamoyl)-2-methyl-indol-1-yl]-acetic acid

[5-Fluoro-3-(4-methoxy-phenylsulfamoyl)-2-methyl-indol-1-yl]-acetic acid

(5-Fluoro-2-methyl-3-phenylsulfamoyl-indol-1-yl)-acetic acid

[3-(3,4-Dichloro-benzylsulfamoyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid

[5-Fluoro-3-(3-methoxy-phenylsulfamoyl)-2-methyl-indol-1-yl]-acetic acid

(5-Fluoro-2-methyl-3-*m*-tolylsulfamoyl-indol-1-yl)-acetic acid

(5-Fluoro-2-methyl-3-*p*-tolylsulfamoyl-indol-1-yl)-acetic acid

[3-(4-Chloro-benzylsulfamoyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid

[3-(Benzyl-methyl-sulfamoyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid

[5-Fluoro-2-methyl-3-(pyridin-3-ylsulfamoyl)-indol-1-yl]-acetic acid;

and the C<sub>1</sub>-C<sub>6</sub> alkyl, aryl, (CH<sub>2</sub>)<sub>m</sub>OC(=O)C<sub>1</sub>-C<sub>6</sub>alkyl, (CH<sub>2</sub>)<sub>m</sub>N(R<sup>11</sup>)<sub>2</sub>,

CH((CH<sub>2</sub>)<sub>m</sub>O(C=O)R<sup>12</sup>)<sub>2</sub> esters of any of the above; wherein

m is 1 or 2;

R<sup>11</sup> is hydrogen or methyl;

R<sup>12</sup> is C<sub>1</sub>-C<sub>18</sub> alkyl.

59. (New) A process for the preparation of a compound of general formula (I) as claimed claim 1 and wherein n is 1 or 2 and X is a bond, the process comprising treating a compound of general formula (Ia), which is a compound of general formula (I) wherein n is 0 and X is a bond, by oxidation with a suitable oxidising agent.

60. (New) A process for the preparation of a compound of general formula (I) as claimed in claim 1, the process comprising reacting a compound of general formula (II) as defined in claim 44 and wherein R<sup>10</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl with a base.

61. (New) A method for the treatment of a disease or condition mediated by the action of PGD<sub>2</sub> at the CRTH2 receptor, the method comprising administering to a patient in need of such treatment a compound as claimed in claim 1 or a compound as claimed in claim 44.

62. (New) The method of claim 61, further comprising administering to the patient one or more additional active agents useful in the treatment of diseases and conditions mediated by PGD<sub>2</sub> at the CRTH2 receptor.

63. (New) The method of claim 62 wherein the additional active agents are selected from the group consisting of  $\beta$ 2 agonists, corticosteroids, antihistamines, leukotriene antagonists, anti-IgE antibody therapies, anti-infectives, anti-fungals, immunosuppressants, other antagonists of PGD<sub>2</sub> acting at other receptors, inhibitors of phosphodiesterase type 4, drugs that modulate cytokine production, drugs that modulate the activity of Th2 cytokines IL-4 and IL-5, PPAR- $\gamma$  agonists and 5-lipoxygenase.

64. (New) The method of claim 63, wherein the additional active agents are selected from the group consisting of salmeterol, fluticasone, loratidine, montelukast, omalizumab, fusidic acid, clotrimazole, tacrolimus, pimecrolimus, DP antagonists, cilionilast, inhibitors of TNF $\alpha$  converting enzyme (TACE), blocking monoclonal antibodies, soluble receptors, rosiglitazone and zileuton.



65. (New) A method for the treatment of a disease or condition selected from the group consisting of allergic asthma, perennial allergic rhinitis, seasonal allergic rhinitis, atopic dermatitis, contact hypersensitivity (including contact dermatitis), conjunctivitis, especially allergic conjunctivitis, eosinophilic bronchitis, food allergies, eosinophilic gastroenteritis, inflammatory bowel disease, ulcerative colitis and Crohn's disease, mastocytosis, autoimmune diseases such as hyper IgE syndrome and systemic lupus erythematus, psoriasis, acne, multiple sclerosis, allograft rejection, reperfusion injury and chronic obstructive pulmonary disease; or rheumatoid arthritis, psoriatic arthritis and osteoarthritis, the method comprising administering to a patient in need of such treatment a compound as claimed in claim 1 or a compound as claimed in claim 44.

66. (New) The method of claim 65, further comprising administering to the patient one or more additional active agents useful in the treatment of diseases and conditions mediated by PGD<sub>2</sub> at the CRTH2 receptor.

67. (New) The method of claim 66 wherein the additional active agents are selected from the group consisting of  $\beta$ 2 agonists, corticosteroids, antihistamines, leukotriene antagonists, anti-IgE antibody therapies, anti-infectives, anti-fungals, immunosuppressants, other antagonists of PGD<sub>2</sub> acting at other receptors, inhibitors of phosphodiesterase type 4, drugs that modulate cytokine production, drugs that modulate the activity of Th2 cytokines IL-4 and IL-5, PPAR- $\gamma$  agonists and 5-lipoxygenase.

68. (New) The method of claim 67, wherein the additional active agents are selected from the group consisting of salmeterol, fluticasone, loratidine, montelukast, omalizumab, fusidic acid, clotrimazole, tacrolimus, pimecrolimus, DP antagonists, cilionilast, inhibitors of TNF $\alpha$  converting enzyme (TACE), blocking monoclonal antibodies, soluble receptors, rosiglitazone and zileuton.

69. (New) A pharmaceutical composition comprising a compound as claimed in claim 1 together with a pharmaceutical excipient or carrier.

70. (New) A composition as claimed in claim 69 formulated for oral, rectal, nasal, bronchial (inhaled), topical (including eye drops, buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration.

71. (New) A composition as claimed in claim 70 formulated for oral, nasal, bronchial or topical administration.

72. (New) A composition as claimed in claim 69 containing one or more additional active agents useful in the treatment of diseases and conditions mediated by PGD<sub>2</sub> at the CRTH2 receptor.

73. (New) A composition as claimed in claim 72, wherein the additional active agents are selected from the group consisting of  $\beta$ 2 agonists, corticosteroids, antihistamines, leukotriene antagonists, anti-IgE antibody therapies, anti-infectives, anti-fungals, immunosuppressants, other antagonists of PGD<sub>2</sub> acting at other receptors, inhibitors of phosphodiesterase type 4, drugs that modulate cytokine production, drugs that modulate the activity of Th2 cytokines IL-4 and IL-5, PPAR- $\gamma$  agonists and 5-lipoxygenase.

74. (New) A composition as claimed in claim 73, wherein the additional active agents are selected from the group consisting of salmeterol, fluticasone, loratidine, montelukast, omalizumab, fusidic acid, clotrimazole, tacrolimus, pimecrolimus, DP antagonists, cilonilast, inhibitors of TNF $\alpha$  converting enzyme (TACE), blocking monoclonal antibodies, soluble receptors, rosiglitazone and zileuton.

75. (New) A pharmaceutical composition comprising a compound as claimed in claim 44 together with a pharmaceutical excipient or carrier.

76. (New) A composition as claimed in claim 75 formulated for oral, rectal, nasal, bronchial (inhaled), topical (including eye drops, buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration.

77. (New) A composition as claimed in claim 76 formulated for oral, nasal, bronchial or topical administration.

78. (New) A composition as claimed in claim 46 containing one or more additional active agents useful in the treatment of diseases and conditions mediated by PGD<sub>2</sub> at the CRTH2 receptor.

79. (New) A composition as claimed in claim 78, wherein the additional active agents are selected from the group consisting of  $\beta$ 2 agonists, corticosteroids, antihistamines, leukotriene antagonists, anti-IgE antibody therapies, anti-infectives, anti-fungals, immunosuppressants, other antagonists of PGD<sub>2</sub> acting at other receptors, inhibitors of phosphodiesterase type 4, drugs that modulate cytokine production, drugs that modulate the activity of Th2 cytokines IL-4 and IL-5, PPAR- $\gamma$  agonists and 5-lipoxygenase.

80. (New) A composition as claimed in claim 79, wherein the additional active agents are selected from the group consisting of salmeterol, fluticasone, loratidine, montelukast, omalizumab, fusidic acid, clotrimazole, tacrolimus, pimecrolimus, DP antagonists, cilionilast, inhibitors of TNF $\alpha$  converting enzyme (TACE), blocking monoclonal antibodies, soluble receptors, rosiglitazone and zileuton.

LAW OFFICES OF  
CHRISTENSEN O'CONNOR JOHNSON KINDNESS<sup>LLC</sup>  
1420 Fifth Avenue  
Suite 2800  
Seattle, Washington 98101  
206.682.8100